IBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
IBIO, INC. (IBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.87 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-28
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-09-30 was $0.85, a 150.00% increase year-over-year.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-09-30 was $0.34.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-09-30 was $0.63, a 53.66% increase year-over-year.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-09-30 was $0.41, a 6.82% decline year-over-year.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2026 was $1.87, a 41.56% decline from fiscal 2025.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $3.20.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $1.25, a 28.87% increase from fiscal 2020.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $0.97, a 0.00% change from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.87 10-K · filed 2026-08-28 | ||||
| 2025-06-30 | $3.20 10-K · filed 2026-08-28 | ||||
| 2021-06-30 | $1.25 10-K · filed 2021-09-28 | ||||
| 2020-06-30 | $0.97 10-K · filed 2021-09-28 | ||||
| 2020-03-31 | $0.99 10-Q · filed 2020-05-15 | ||||
| 2019-06-30 | $0.97 10-K · filed 2020-10-13 | $0.43 10-K · filed 2019-08-26 | |||
| 2019-03-31 | $0.87 10-Q · filed 2019-05-10 | ||||
| 2018-12-31 | $0.75 10-Q · filed 2019-02-13 | ||||
| 2018-09-30 | $0.85 10-Q · filed 2018-11-13 | ||||
| 2018-06-30 | $0.43 10-K · filed 2020-10-13 | $2.77 10-K · filed 2018-09-18 | |||
| 2018-03-31 | $0.34 10-Q · filed 2018-05-11 | ||||
| 2017-12-31 | $0.34 10-Q · filed 2018-02-14 | ||||
| 2017-09-30 | $0.34 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $0.36 10-K · filed 2018-09-18 | ||||
| 2016-06-30 | $0.62 10-K · filed 2017-09-15 | ||||
| 2016-03-31 | $0.62 10-Q · filed 2016-05-23 | ||||
| 2015-12-31 | $0.63 10-Q · filed 2016-02-22 | ||||
| 2015-09-30 | $0.63 10-Q · filed 2015-11-13 | ||||
| 2015-06-30 | $0.43 10-K · filed 2016-10-13 | ||||
| 2015-03-31 | $0.43 10-Q · filed 2015-05-15 | ||||
| 2014-12-31 | $0.43 10-Q · filed 2015-02-24 | ||||
| 2014-09-30 | $0.41 10-Q · filed 2014-11-14 | ||||
| 2014-06-30 | $0.40 10-K · filed 2015-10-13 | ||||
| 2014-03-31 | $0.40 10-Q · filed 2014-05-15 | ||||
| 2013-12-31 | $0.36 10-Q · filed 2014-02-14 | ||||
| 2013-09-30 | $0.44 10-Q · filed 2013-11-14 | ||||
| 2013-06-30 | $0.90 10-K · filed 2014-09-29 | ||||
| 2013-03-31 | $0.90 10-Q · filed 2013-05-20 | ||||
| 2012-12-31 | $0.64 10-Q · filed 2013-02-19 | $0.92 10-Q · filed 2013-02-19 | |||
| 2012-09-30 | $0.96 10-Q · filed 2012-11-14 | ||||
| 2012-06-30 | $1.56 10-K/A · filed 2013-10-04 | ||||
| 2011-06-30 | $1.98 10-K/A · filed 2012-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |